Bridging the translational innovation gap through good biomarker practice
Nat Rev Drug Discov
.
2017 Sep;16(9):587-588.
doi: 10.1038/nrd.2017.72.
Epub 2017 Apr 28.
Authors
Alain J van Gool
1
,
Florence Bietrix
2
,
Eric Caldenhoven
3
,
Kurt Zatloukal
4
,
Andreas Scherer
5
,
Jan-Eric Litton
6
,
Gerrit Meijer
7
,
Niklas Blomberg
8
,
Andy Smith
8
,
Barend Mons
9
,
Jaap Heringa
10
,
Wim-Jan Koot
3
,
Martin J Smit
11
,
Marian Hajduch
12
,
Ton Rijnders
3
,
Anton Ussi
2
Affiliations
1
Radboud University Medical Center, Nijmegen, TNO, 3704 HE Zeist, The Netherlands.
2
EATRIS-ERIC, 1081 HZ Amsterdam, The Netherlands.
3
Lygature, 3521 AL Utrecht, The Netherlands.
4
Medical University of Graz, 8036 Graz, Austria.
5
Institute for Molecular Medicine Finland (FIMM), University of Helsinki, FI-00014 Helsinki, Finland.
6
BBMRI-ERIC, 8010 Graz, Austria.
7
Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
8
ELIXIR, Hinxton CB10 1SD, UK.
9
Leiden University Medical Centre, 2333 ZA Leiden, The Netherlands.
10
VU University, 1081 HV Amsterdam, The Netherlands.
11
University of Groningen, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands.
12
Institute of Molecular and Translational Medicine (IMTM), Palacky University, 779 00 Olomouc, Czech Republic.
PMID:
28450744
DOI:
10.1038/nrd.2017.72
No abstract available
MeSH terms
Biomarkers*
Drug Discovery* / methods
Drug Discovery* / trends
Humans
Inventions*
Molecular Targeted Therapy / methods
Molecular Targeted Therapy / trends
Translational Research, Biomedical
Substances
Biomarkers